Drug therapy for survivors of sudden cardiac death.
The proliferation of standard as well as novel community based systems for resuscitation of victims of out-of-hospital cardiac arrest has provided a large group of sudden cardiac death survivors who present a therapeutic challenge. The nature and severity of the underlying heart disease must be delineated. Particularly, myocardial ischemia and congestive heart failure must be controlled. Prior to considering device therapy of surgical intervention, pharmacologic therapy should be evaluated. Baseline electrophysiological studies determine the applicability of serial pharmacologic testing. In patients with inducible VT/VF, serial electrophysiological testing can identify drug regimens that prevent the arrhythmia in approximately 40% of patients. In an additional 20% of patients, regimens which slow the ventricular tachycardia and significantly reduce the arrhythmia related mortality can be identified. Three to 5-year follow-up has shown such an approach can reduce the sudden death mortality in these patients to less than 3% per year. It has been suggested that certain medication, most notably amiodarone, electrophysiological testing has not been useful in assessing efficacy. Several recent studies, however, have shown that electrophysiological testing is indeed useful even in evaluating the efficacy of amiodarone. In patients in whom ventricular tachycardia/ventricular fibrillation cannot be prevented or significantly slowed, medical therapy is generally ineffective and the sudden death mortality is 20% to 40% per year. In such patients, other therapeutic modalities should be considered.
Horowitz
L N
LN
Philadelphia Heart Institute, Presbyterian-University of Pennsylvania, Pennsylvania 19104.
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000517:prevention & control*; D002304:Cardiac Pacing, Artificial; D003645:Death, Sudden; D004594:Electrophysiology; D005500:Follow-Up Studies; D006323:Heart Arrest; D006334:Heart Function Tests; D006801:Humans
D000889:Anti-Arrhythmia Agents